631. Using a commercially available assay that measures cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity to predict protection against CMV: Results from a prospective, blinded clinical trial

BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality among kidney transplant recipients (KTR). Given toxicities and costs of antivirals, there is growing interest in assays that measure CMV-specific T-cell immunity (TCI), which may predict protection aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Almaghlouth, Nouf K, Arvanitis, Panos, Vieira, Kendra, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678232/
http://dx.doi.org/10.1093/ofid/ofad500.697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678232/
http://dx.doi.org/10.1093/ofid/ofad500.697

Ejemplares similares